TCR2 Therapeutics Statistics Share Statistics TCR2 Therapeutics has 39.26M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 39.26M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 26.75M Failed to Deliver (FTD) Shares 61 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 548.1K, so 0% of the outstanding
shares have been sold short.
Short Interest 548.1K Short % of Shares Out n/a Short % of Float 1.75% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.25 and the forward
PE ratio is null.
TCR2 Therapeutics's PEG ratio is
-0.01.
PE Ratio -0.25 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.27 P/FCF Ratio -0.33 PEG Ratio -0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for TCR2 Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.77,
with a Debt / Equity ratio of 0.38.
Current Ratio 2.77 Quick Ratio 2.77 Debt / Equity 0.38 Debt / EBITDA -0.6 Debt / FCF -0.46 Interest Coverage -2.61
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.62M Employee Count 58 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 261K Effective Tax Rate -0.17%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.93, so TCR2 Therapeutics's
price volatility has been higher than the market average.
Beta 1.93 52-Week Price Change n/a 50-Day Moving Average 1.69 200-Day Moving Average 1.64 Relative Strength Index (RSI) 27.34 Average Volume (20 Days) 325,040
Income Statement
Revenue n/a Gross Profit n/a Operating Income -153.5M Net Income -151.82M EBITDA -89.62M EBIT -92.67M Earnings Per Share (EPS) -3.93
Full Income Statement Balance Sheet The company has 32.75M in cash and 53.76M in
debt, giving a net cash position of -21.02M.
Cash & Cash Equivalents 32.75M Total Debt 53.76M Net Cash -21.02M Retained Earnings -501.34M Total Assets 151.51M Working Capital 93.02M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -101.46M
and capital expenditures -15.45M, giving a free cash flow of -116.91M.
Operating Cash Flow -101.46M Capital Expenditures -15.45M Free Cash Flow -116.91M FCF Per Share -3.03
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
